A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study

A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study

Background: Approximately 10% of patients with non-small cell lung cancer (NSCLC) are complicated with comorbid interstitial pneumonia (IP) with a poor prognosis. The pharmacotherapy for advanced lung cancer occasionally induces fatal acute exacerbation of pre-existing IP. Due to the lack of prospec...

Full description

Bibliographic Details
Main Authors: Satoshi Ikeda, Terufumi Kato, Hirotsugu Kenmotsu, Takashi Ogura, Shunichiro Iwasawa, Tae Iwasawa, Rika Kasajima, Yohei Miyagi, Toshihiro Misumi, Takeharu Yamanaka, Hiroaki Okamoto
Format: Article
Language:English
Published: SAGE Publishing 2020-05-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920922022

Internet

https://doi.org/10.1177/1758835920922022

Similar Items